1. Introduction
===============

Colorectal cancer (CRC) is one of the most frequently diagnosed cancer in the world with \>1.3 million new diagnoses and 694,000 deaths in 2012.^\[[@R1]\]^ Both as monotherapy or in combination with chemotherapy, biological agents have been widely researched in metastatic colorectal cancer.^\[[@R2]--[@R4]\]^ Inconsistent results from clinical trials have been supposed to involve the interaction with chemotherapy partners, including anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) and anti-angiogenesis inhibitors.^\[[@R5]--[@R7]\]^

Activating mutations in RAS except for the KRAS mutations is also considered to be the negative predictive biomarkers for EGFR antibodies. Based on the existing mutational and biochemical data, it\'s biologically plausible. More clinical data have also shown mutations in RAS predict a lack of benefit to panitumumab or cetuximab. In a updated analysis of the PRIME trial, in patients with mCRC and mutated RAS, panitumumab plus oxaliplatin-based regimens have no value.^\[[@R8]\]^ BRAF V600E, which is typically exclusive of RAS mutations, is clearly predictive of poor prognosis in mCRC, but not insufficient to justify the exclusion of the EGFR antibodies, in patients with metastatic colorectal cancer.^\[[@R9]--[@R12]\]^

More and more evidences reveal tumors arising from different sides of the colon are molecularly and clinically distinct.^\[[@R13]--[@R17]\]^ With the availability of genomic platforms capable of broadly surveying gene expression and methylation, 4 consensus molecular subtypes (CMSs) emerged.^\[[@R18]\]^ CMS1, which is predominantly composed of right-sided CRCs, and enriched for MSI-high, CIMP-high, and BRAF mutation, are associated with worse survival. High tumor expression of AREG and EREG is linked to greater response rates and improved outcomes with anti-EGFR mAb in patients with RAS wild-type mCRCs^\[[@R19],[@R20]\]^ and left-sided CRCs have a significantly higher EREG and AREG expressions.^\[[@R13],[@R21],[@R22]\]^ Differential distribution of these genomic CRC subtypes and other biologic features among right- and left-sided CRCs may contribute to the inferior prognosis of advanced-stage right-sided CRCs and an inferior outcome with anti-EGFR therapy in right-sided CRC.^\[[@R23]\]^

There are several randomized controlled clinical trials, which have shown confusing findings about whether the efficacy is improved by adding panitumumab or cetuximab to oxaliplatin-based regimens in KRAS wild mCRC.^\[[@R24]--[@R28]\]^ Many scholars believe that the efficacy of the EGFR antibody combined with oxaliplatin-based regimen in the treatment of KRAS wild mCRC have been limited, and oxaliplatin may not be the appropriate compatible drug for the combined cetuximab. Some scholars also pointed out that oxaliplatin can strongly and continuously activate Src gene, making cetuximab can not play the desired anti-tumor effect, resulting in drug resistance.^\[[@R29],[@R30]\]^ However, the PRIME trial reveals that in mCRC patients without any RAS mutations, improvements were observed in overall survival by comparing panitumumab plus FOLFOX4 versus FOLFOX4. Considering the same mechanism binding of antibodies on EGFR that prevents the dimerization and the activation of EGFR, it\'s confused why there is a conflicting result.

The purpose of this study is to evaluate the efficacy of the addition of anti-EGFR mAb to oxaliplatin-based regimens in RAS wild type patients with metastatic colorectal cancer for the first-line treatment. The primary tumor location and BRAF status is considered.

2. Methods
==========

2.1. Search strategy
--------------------

Search is limited to randomized controlled trials. Medline, EMBASE, Cochrane library were searched using subject headings and key words including: metastatic colorectal cancer, mCRC, cetuximab, panitumumab, oxaliplatin, ras-wild, FOLFOX, XELOX, FLOX. The latest search was done on October, 2017. Further more, major oncological conferences in ASCO, ASCO GI, ESMO were searched manually. Relevant MeSH terms (Medical Subject Headings) were used where possible. The search is limited in English. Duplication and irrelevant studies were excluded.

2.2. Inclusion and exclusion criteria
-------------------------------------

In this meta-analysis, a study should meet the following criteria: only randomized clinical trials evaluating the oxaliplatin-based regimen with or without EGFR antibodies in the first-line treatment of RAS wild mCRC; a study should include the following information: ORR, PFS, OS. Case reports, reviews, cohort studies, and irrelevant articles were excluded. FOLFOXRI regimen is excluded due to the containing of the irinotecan.

From the results obtained, five randomized controlled trials evaluating the oxaliplatin-based regimens with or without EGFR antibodies in the first-line treatment of mCRC were selected for a meta-analytic evaluation.

2.3. Data extraction and objectives
-----------------------------------

The following characteristics were collected: first author, year of publication, chemotherapy regimens, number of patients, overall response rate (ORR), progression-free survival (PFS), overall survival (OS), follow-up period, RAS and BRAF status, primary tumor location. The primary objective of this meta-analysis was to analyze the addition of panitumumab or cetuximab to the oxaliplatin-based regimen in the first-line treatment of RAS-wild and RAS/BRAF wild mCRC. ORR, PFS, OS were considered where data are available. The impact of primary tumor location was considered into this meta-analysis. The splenic flexure was used to distinguish tumor sideness. All analyses were done according to previous published studies, so there are no patient consent and ethical approval required. We follow the guidelines by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement.

2.4. Statistical methods
------------------------

All meta-analyses were carried out with Review Manager 5.3 (Nordic Cochrane Center, Copenhagen, Denmark). Time to event outcomes of PFS and OS were reported using HRs with random-effects model. For ORR, odds radio (OR) was also used with random-effects model. HRs \>1 favored the anti-EGFR whereas HRs \<1 favored the chemotherapy alone. ORs for ORR \>1 reflected a higher overall response in the anti-EGFR mAb arm. Respective 95% CIs and *P*-values were presented in the forest plot. The heterogeneity among these studies was assessed by the chi-square and I-square test, which was defined as *P* \< .1 or *I*^2^ \>50%. If the heterogeneity was detected, possible explanation was explored.

Only 5 RCTs were included in this meta-analysis, so we didn't perform a funnel plot to evaluate the publication bias. However, these are all high quality research, and we believe the result is stable to overcome the publication bias.

3. Results
==========

3.1. Overview of the included trials
------------------------------------

Five first-line trials including 7 articles met the inclusion criteria with usable informations through searching the related references and databases: PRIME (NCT00364013),^\[[@R8],[@R31]\]^ NORDIC VII study (NCT00145314),^\[[@R32]\]^ TAILOR (NCT01228734),^\[[@R33],[@R34]\]^ COIN (ISRCTN27286448),^\[[@R26]\]^ OPUS (NCT00125034)^\[[@R35]\]^ (Table [1](#T1){ref-type="table"}). They are all of high quality, and the efficacy of cetuximab or panitumumab was analyzed according to the RAS and BRAF status. The OS, PFS, ORR of these patients were extracted from 5 trials where available.

###### 

Source of patients for the analyses.
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Three trials (TAILOR, PRIME, and OPUS) reported the outcome of differential treatments in RAS-wild patients by comparing FOLFOX plus anti-EGFR mAbs versus FOLFOX. Five trials evaluated the clinical outcomes in EGFR antibodies-treated mCRC for RAS/BRAF wild patients. In this group, a subgroup analysis could be performed according to the fluoropyrimidine regimens.

According to the PTL subgroup, 2 trials (TAILOR and PRIME) reported the outcome in the differential treatment arms (Table [2](#T2){ref-type="table"}). A meta-analysis of PRIME and TAILOR study assessed the predictive role of PTL for anti-EGFR mAbs combined with FOLFOX were performed.

###### 

Treatment effects within subgroups defined by primary tumor location (PTL) in patients with RAS wild-type metastatic colorectal cancer.
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3.2. Meta-analysis results
--------------------------

### 3.2.1. Anti-EGFR mAb improve the efficacy combined with FOLFOX

A total of 4109 patients were evaluated in the 5 trials, but the total number of patients included in this meta-analysis was 992 for RAS wild-type and 1236 for RAS/BRAF wild-type. The characteristics of these studies are shown in Table [1](#T1){ref-type="table"}. The main result of our meta-analysis is the addition of EGFR antibody to oxaliplatin-based chemotherapy (FOLFOX) in RAS wild-mCRC patients for the first-line treatment lead to significant improvements in PFS (HR = 0.70; 95% CI, 0.59--0.82; *P* \< .0001; Fig. [1](#F1){ref-type="fig"}A) and OS (HR = 0.79; 95% CI, 0.67--0.92; *P* = .003; Fig. [1](#F1){ref-type="fig"}B) compared with chemotherapy alone. The odds ratio for ORR also favored EGFR antibody therapy (OR = 2.56; 95% CI, 1.77--3.70; *P* \< .0001, Fig. [1](#F1){ref-type="fig"}C).

![Forest plots for predictive analyses in trials comparing chemotherapy plus EGFR antibody therapy with chemotherapy alone in RAS-wild patients. (A) progression-free survival, (B) overall survival, and (C) objective response rate. CI = confidence interval, CT = chemotherapy, EGFR = epidermal growth factor receptor, HR = hazard ratio, OR = odds ratio.](medi-97-e0097-g003){#F1}

In RAS/BRAF-wild patients, a subgroup analysis of the type of fluoropyrimidine regimen was performed. The HR for PFS and OS were not significant when anti-EGFR mAbs were added to XELOX regimen (PFS, HR = 1.02; 95% CI, 0.82--1.26; *P* = .88, Fig. [2](#F2){ref-type="fig"}A) or FLOX (OS, HR = 1.07; 95% CI, 0.74--1.55; *P* = .72, Fig. [2](#F2){ref-type="fig"}B; PFS, HR = 1.06; 95% CI, 0.73--1.55; *P* = .75, Fig. [2](#F2){ref-type="fig"}A) compared with chemotherapy alone, while PFS and OS obviously improved with an FOLFOX regimen (OS, HR = 0.77; 95% CI, 0.61--0.98; *P* = .03; PFS, HR = 0.68; 95% CI, 0.57--0.82; *P* \< .0001). There was significantly difference among the 3 subgroups (*P* = .009) when the PFS of EGFR antibodies plus chemotherapy versus chemotherapy alone was analyzed according to different fluoropyrimidine regimens.

![Forest plots for predictive analyses in trials comparing chemotherapy plus EGFR antibody therapy with chemotherapy alone in RAS/BRAF wild patients. (A) progression-free survival, (B) overall survival. CI = confidence interval, CT = chemotherapy, EGFR = epidermal growth factor receptor, HR = hazard ratio, OR = odds ratio.](medi-97-e0097-g004){#F2}

### 3.2.2. Predictive implications of tumor location for anti-EGFR treatment

To evaluate the predictive implications of primary tumor location on differential treatment arms, a meta-analysis based on 2 trials could be performed (TAILOR and PRIME). This meta-analysis analyzed the treatment efficacy on PFS, OS, and ORR by comparing EGFR antibody plus FOLFOX with FOLFOX alone (Fig. [3](#F3){ref-type="fig"}). With regard to PFS, OS, and ORR, the analysis displayed a significant benefit from anti-EGFR mAb for RAS wild left-sided tumors in the first-line treatment. The HRs for PFS and ORR in right-sided tumor were also favorable of the anti-EGFR mAb+FOLFOX. There was no significant study heterogeneity for the 3 endpoints.

![Forest plots showing hazard ratio (HR) for progression-free survival (PFS; A--B), overall survival (OS; C--D), and overall response rate (ORR; E--F) comparing FOLOFX plus anti-EGFR antibody with FOLFOX for the subgroups of left-sided and right-sided colorectal cancer.](medi-97-e0097-g005){#F3}

4. Discussion
=============

The presented analysis finds that the combination of Anti-EGFR mAb and FOLFOX supports a potential benefit for patients wild RAS-wild mCRC, compared with FOLFOX alone. In RAS/BRAF-wild mCRC, additional subgroup analysis was evaluated according to the type of fluoropyrimidine regimen (FOLFOX, XELOX, and FLOX) in RAS/BRAF wild mCRC. It became evident that the differences in PFS and OS were not significant when EGFR antibody was added to FLOX or XELOX regimen compared with chemotherapy alone, but PFS and OS were improved with FOLFOX treatment. It should, however, be noted that only 1 clinical trial evaluate the XELOX or FLOX plus cetuximab as compared with chemotherapy alone, respectively. Due to the limited clinical data, definitive conclusions cannot be drawn.

There have been 2 other recent meta-analyses evaluating anti-EGFR mAb with oxaliplatin-based chemotherapy regimens in KRAS-wild mCRC.^\[[@R6],[@R36]\]^ The first shows that no survival benefit was observed in KRAS wild mCRC patients in first-line treatment when adding panitumumab or cetuximab to oxaliplatin-based chemotherapy. The second meta-analysis, which included the same 4 trials as the first study, demonstrated that EGFR mAb combined with FOLFOX regimen as first-line treatment was associated with a significant improvement on PFS and OS in KRAS wild mCRC. However, it\'s still controversial with regard to this issue. The present meta-analysis adds to this by including updated ORR, PFS, OS data restricted to RAS-wild or RAS/BRAF wild mCRC and incorporating an extra data from TAILOR study.

In MRC COIN study, additional predictive factor analysis reveals improved PFS with cetuximab was noticed in fluorouracil-based subgroup while the capecitabine-based therapy shows a negative result. One explanation may be that increased toxicity from capecitabine-based regimen resulted in decreased dose intensity and impaired efficacy. Patients given capecitabine-based therapy (XELOX) in the COIN trial were treated with a shorter treatment duration for median 25 weeks, whereas 29 weeks in fluorouracil-based therapy group (FOLFOX).^\[[@R26]\]^ The higher rate of adverse effects than expected led the reduction dose of capecitabine from 1000 to 850 mg/m^2^ Bid in a protocol amendment only for patients in XELOX plus cetuximab.^\[[@R26]\]^ It is also particularly noted that in patients treated with XELOX plus cetuximab, 33% of patients reduced the oxaliplatin dose compared with 15% treated with XELOX alone.^\[[@R37]\]^ In fact, some clinical studies demonstrated cetuximab plus XELOX is a effective and tolerable treatment regimen.^\[[@R38]--[@R40]\]^

In view of the result from NORDIC-VII, a FLOX regimen was used. There are no obvious explanations for the discrepant findings. Thus, a positive pharmacodynamic synergism may be existed between the EGFR antibody and fluoropyrimidine administered via the FOLFOX chemotherapy, which was not achieved through a bolus 5-FU regimen as the chemotherapy backbone. Lack of efficacy when cetuximab was added to FLOX strengthens the viewpoint that this combination may be not suitable and strongly implies FLOX regimen has a negative interaction with cetuximab.

Previous researches have suggested that tumor location has a prognostic role and predicts the efficacy of targeted therapy in mCRC patients. This is the first report evaluating the impact of tumor location on clinical outcomes for patients receiving FOLFOX plus EGFR antibody compared with FOLFOX alone. Data from 2 first-line randomized clinical trials (PRIME and TAILOR) were analyzed according to the tumor location. The evidence obviously demonstrates that benefits from EGFR antibody were markedly greater in left-sided tumors compared with those right-sided tumors, however the HR for PFS and the OR for ORR consistently suggested a benefit that presents a trendency in favor of anti-EGFR mAb.

Regarding the predictive role of tumor location on efficacy of EGFR antibodies, most recent data arises from first-line studies through comparing chemotherapy with either cetuximab or bevacizumab in RAS-wild mCRC. In CALGB 80405 clinical trial, clinical outcomes were consistently superior for PFS and OS in left-sided colorectal cancers compared with those right-sided colorectal cancers. Among the cetuximab group, left-sided mCRC was associated with better OS that reaches 25.7 months comparing with right-sided tumors with a statically significant difference (HR, 1.82, *P* \< .001). Furthermore, in left-sided mCRC, FOLFOX plus cetuximab appears to be significantly superior to FOLFOX plus bevacizumab for OS. Conversely, right-sided mCRCs had better outcomes in bevacizumab-treated arm.^\[[@R41]\]^ A meta-analysis conducted by Holch, which assessed the prognostic and predictive role of tumor location in patients with mCRC treated with first-line therapy, demonstrates primary tumor location has a prognostic value in mCRC. Furthermore, it supports the viewpoint that RAS-wild mCRC patients with left-sided tumors should be firstly treated with an EGFR antibody, and in right-sided tumors, bevacizumab-based treatment numerically associates with better survival and the benefits from standard therapy was limited. Interestingly, the contrary was found for ORR which favored anti-EGFR therapy.^\[[@R42]\]^ Another meta-analysis also confirms the observation that anti-EGFR disease control expression signature was associated with left-sided tumor location, and RAS-wild mCRC patients with right-sided tumors might benefit from bevacizumab compared with panitumumab or cetuximab in terms of PFS, OS, but not for ORR.^\[[@R43]\]^ We also notice the addition of cetuximab to FOLFIRI in RAS-wild right-sided patients was linked with non-significant numerical advantage with regard to PFS and ORR in the CRYSTAL trial.^\[[@R44]\]^ This promotes the notion that patients with right-sided tumors might be preferentially treated with anti-EGFR mAb plus chemotherapy if the goal is to reduce the tumor size since the ORR was higher, which is important to increase the resectability of non-resectable liver metastases of colorectal cancer.

We acknowledge several limitations of the present investigation: first, the most studies are retrospective and exploratory. Second only 5 studies were included in this analysis and study-level data were utilized rather than patient-level data. Also, when considering the patients with left-sided and right-sided tumors separately, there are some small imbalances in baseline characteristics. Therefore, we ought to interpret the results with adequate caution.

5. Conclusion
=============

In summary, FOLFOX plus anti-EGFR mAb is an effective first-line treatment for patients with RAS-wild left-sided mCRC. For patients with right-sided disease, it is not possible to draw definitive conclusions on optimal treatment based on the present analyses. Much more prospective clinical trials are required to confirm a potential subgroup of patients with right-sided mCRC who might benefit from anti-EGFR mAb.

Abbreviations: EGFR = epidermal growth factor receptor, mAbs = monoclonal antibodies, mCRC = metastatic colorectal cancer, ORR = overall response rate, OS = overall survival, PFS = progression-free survival, PTL= primary tumor location.

The authors report no conflicts of interest in this work.
